Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial

NCT01836523 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT01836523
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01836523 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial
Lead sponsor
Novo Nordisk A/S
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2013
Completion date
June 30, 2015
Enrollment
1,398 (actual)
Sites
182

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes, diabetes mellitus, type 1